By Uduak Grace Thomas

Bioinformatics startup PanGenX is betting that its semantic approach to data integration will ultimately help drug developers and diagnostic firms develop more personalized treatments.

The firm, based in Auburndale, Mass., intends to help pharma and diagnostic customers integrate proprietary and public data in "meaningful ways" and then run analyses that reveal information on individuals' responses to treatment, Jeremy Sohn, PanGenX's chief operating officer, explained to BioInform this week

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: factors affecting the success of whole-genome sequencing for routine clinical diagnosis, and more.

A large meta-analysis from an international team reports that nature and nurture have about an equal overall influence on human traits.

The Lasker Foundation's Claire Pomeroy laments the state of NIH funding at Forbes.

Social media is changing how scientists discuss research, as tweets from University of Chicago's Yoav Gilad about a Mouse ENCODE paper have shown, Nature reports.

May
28
Sponsored by
PerkinElmer

This online seminar will demonstrate how RNA-seq analysis in a model organism can provide insights into human disease. 

Jun
23
Sponsored by
PerkinElmer

This webinar will demonstrate how automated liquid handling workstations can reduce bottlenecks in library preparation for next-generation sequencing, enabling scientific advances in genomics research that were not possible five years ago.